Loading patent…
AssigneeLife Technologies Corporation
InventorsXin YU, Xavier de MOLLERAT du JEU, Chao Yan Liu, jJian Liu, Jonathan Zmuda
Estimating the term…
The instant technology relates to a production system to produce AAV vectors in a serum free suspension platform and at high titers. This technology uses reagents comprising media, cells, transfection reagent, AAV enhancer, and a lysis buffer, each of which is designed to provide maximal AAV production from suspension culture of mammalian cells, e.g. HEK293 cells. With this new system we are able to deliver up to about 2×1011 viral genomes per milliliter (vg/mL) of unconcentrated AAV vectors.
A method for adeno-associated virus (AAV) vector production, the method comprising:
3-5. (canceled)
8-9. (canceled)
(canceled)
13-14. (canceled)
(canceled)
18-20. (canceled)
(canceled)
24-35. (canceled)
An adeno-associated virus (AAV) production system, comprising:
(canceled)
(canceled)
(canceled)
45-46. (canceled)
48-64. (canceled)
A kit for adeno-associated virus (AAV) production, the kit comprising:
69-73. (canceled)
Dependencies are inferred from the claim text.